Stay updated on RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial

Sign up to get notified when there's something new on the RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety and efficacy comparison of RGN-259 Ophthalmic Solution to placebo for the treatment of dry eye syndrome in the ARISE-3 clinical study.
    Difference
    0.1%
    Check dated 2024-06-06T14:43:04.000Z thumbnail image
  7. Check
    22 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying age, consent, and history of dry eye conditions. Previously, no information was provided in this section.
    Difference
    16%
    Check dated 2024-05-22T21:34:31.000Z thumbnail image
  8. Check
    44 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:34:04.000Z thumbnail image

Stay in the know with updates to RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial

Enter your email address, and we'll notify you when there's something new on the RGN-259 Ophthalmic Solutions for Dry Eye Syndrome Clinical Trial page.